FENC Stock Analysis: Buy, Sell, or Hold?
FENC - Fennec Pharmaceuticals Inc. Common Stock
$6.42
0.01 (0.16%)
▲
5d:
-1.38%
30d:
-21.71%
90d:
-16.62%
HOLD
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 12, 2026
Get Alerted When FENC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: FENC shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: FENC shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$20.27
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$12.58
49.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FENC is currently trading at $6.42, which is considered oversold relative to its 30-day fair value range of $6.57 to $8.42. From a valuation perspective, the stock is trading at a discount (Forward PE: 7.1) compared to its historical average (11.5). Remarkably, the market is currently pricing in an annual earnings decline of 14.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, FENC is showing sideways momentum. Immediate support is located at $5.65, while resistance sits at $7.66.
Market Sentiment: FENC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $15.17 (+136.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, FENC is showing sideways momentum. Immediate support is located at $5.65, while resistance sits at $7.66.
Market Sentiment: FENC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $15.17 (+136.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$6.57 -
$8.42
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 136.2% below Wall St target ($15.17)
Fair Price Analysis
30-Day Fair Range
$6.57 -
$8.42
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$5.65
Resistance Level
$7.66
Current Trend
Sideways
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.09
Wall Street Target
$15.17
(+136.2%)
Revenue Growth (YoY)
73.8%
Profit Margin
-21.8%
Valuation Discount vs History
-14.9% cheaper
PE vs Historical
7.1 vs 11.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-14.9%
(market-implied from PE analysis)
1-Year Target
$5.78
(-10%)
2-Year Target
$5.20
(-19%)
3-Year Target
$4.68
(-27%)
3-Yr Target (if PE normalizes)
(PE: 7→12)
$7.59
(+18%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.6, Growth: 314.6%)
$62.83
(+879%)
Base:
(SPY PE: 7.1, Growth: 314.6%)
$21.67
(+238%)
Bear:
(PE: 6.0, Growth: 314.6%)
$18.42
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.1 to 11.5
Stabilization Target:
$10.41
(+62.1%)
PE Expansion Potential:
+62.1%
Share & Embed Analysis
Last updated: April 02, 2026 11:01 PM ET
Data refreshes hourly during market hours. Next update: 12:01 AM
Data refreshes hourly during market hours. Next update: 12:01 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FENC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Rosty Raykov
SELL
10349 shares
2026-02-02
Southpoint Capital Advis…
SELL
1000000 shares
2025-12-24
Rosty Raykov
SELL
10000 shares
2025-12-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 52 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
